ProductDescription
Lacosamideisasmallpeptide-basedagentwithadualmodeofactionforanticonvulsiveandantiepileptictreatment.Lacosamidebindsweakly(25-50%inhibitionofrADIoligandbinding)tothesodiumchannelatbatrachotoxinsite2.Itselectivelyenhancessodiumchannelslowinactivationwithnoeffectsonfastinactivation.Thisslowmodeofactioncanleadtonormalizationofactivationthresholdsandareducedpathophysiologicalhyperresponsiveness.Lacosamidewasalsoshowntobeabindingpartnertocollapsin-responsemediatorprotein2(CRMP-2orDRP-2)withabindingaffinityof5uM.[1]
ExtensivebindingstudieshaveshownthatLacosamideanditsmetabolitesdonotsignificantlybindtoanyoftheknownbindingsitesofotheranticonvulsantoranalgesicagents.FurThermore,itexperiencesnouptakeormetabolisminmajorneurotransmitters.[2]
Lacosamideisalsobeingstudiedinanimalmodelsofpainandinflammation.
Technicalinformation:
| ChemicalFormula: | C13H18N2O3 | |
| CAS#: | 175481-36-4 | |
| MolecularWeight: | 250.29 | |
| Purity: | >98% | |
| Appearance: | White | |
| ChemicalName: | (2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide | |
| Solubility: | Upto22mMinDMSO | |
| Synonyms: | SPM-927,SPM927,Lacosamide,Erlosamide,Harkoseride,Vimpat |
ShippingCondition:Theproductisshippedinaglassvialatambienttemperature.
Storagecondition:Forlongershelflife,storesolidpowderat4oCdesiccated,orstoreDMSOsolutionat-20oC.
Reference:
| 1. | Beyreutheretal.,Lacosamide:areviewofpreclinicalproperties.CNSDrug,2007,13(1),21-42.PubmedID:17461888 |
| 2. | Kellinghausetal.,Lacosamideastreatmentforpartialepilepsy:mechanismsofaction,pharmacology,effects,andsafety.Therapeut.Clin.RiskMgmt.2009,5,757-766.PubmedID:19816574 |
Cellagen的ChamQ SYBR qPCR预混液（无ROX）| Q321产品描述ChamQSYBR®qPCR预混液（Vazyme，＃Q321）由香槟Taq DNA聚合酶（Vazyme，＃P122）通过抗体修饰的热启动激活技术保护，是专为基于SYBR Green I的定量PCR（qPCR）设计的。ChamQSYBR®qPCR Master Mix的优化缓冲液系统中的独特因素（即促进特异性的Exactor）大大提高了其灵敏度和特异性。该混合物以2倍反应浓度制备，可直接用于鲁棒性低模板qPCR，具有高灵敏度，特异性和可靠性。优点特异性+敏感性的最佳组合。独特的抗体修饰的热启动taq，具有独特的特异性促进因子。Mg2 +和染料的最佳浓度。
